RECRUITING

Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main purpose of research is to examine and understanding the development of hypertension in obese adults with insulin resistance. Findings from our studies will identify unique mechanisms that can be targeted to limit increases in vascular dysfunction and reduce the excessively high prevalence of hypertension and risk for cardiovascular disease (CVD). This study is testing the health of the blood vessels and the activity of the nerves that control the blood vessels in adults with insulin resistance. The extent to which ascorbic acid (Vitamin C) improves the function of the blood vessels will be determined. The primary outcome is blood pressure, which is the result of blood vessel health and activity of the nerves, and the reduction in blood pressure that is observed with ascorbic acid.

Official Title

Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance

Quick Facts

Study Start:2021-06-17
Study Completion:2025-04-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04715022

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:35 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Obese: BMI \>30 m/kg2
  2. 2. Middle-aged: 35-65 years
  3. 3. Participants must be willing and able to discontinue taking any vitamin C or E supplements or omega-3 fatty acids beginning 2 weeks prior.
  4. 4. Able and willing to provide written informed consent
  1. 1. Diabetes mellitus: fasting glucose \< 1267 mg/dL and/or HbA1c \< 6.5%
  2. 2. Currently taking a statin or antihypertension medication
  3. 3. Hyperlipidemia: Fasting triglycerides \< 250 mg/dL
  4. 4. Hypertension: \<130/80 mmHg
  5. 5. History of heart disease (e.g., myocardial infarction, stent)
  6. 6. History of vascular disease (e.g., bypass, stroke)

Contacts and Locations

Study Contact

Seth Holwerda, PhD
CONTACT
9729223230
sholwerda@kumc.edu
Manuel Clark, MPA
CONTACT
913-945-5763
mclark16@kumc.edi

Principal Investigator

Seth Holwerda, PhD
PRINCIPAL_INVESTIGATOR
University of Kansas Medical Center

Study Locations (Sites)

University of Kansas Medical Center
Kansas City, Kansas, 66160
United States

Collaborators and Investigators

Sponsor: University of Kansas Medical Center

  • Seth Holwerda, PhD, PRINCIPAL_INVESTIGATOR, University of Kansas Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-06-17
Study Completion Date2025-04-01

Study Record Updates

Study Start Date2021-06-17
Study Completion Date2025-04-01

Terms related to this study

Additional Relevant MeSH Terms

  • Hypertension
  • Cardiovascular Diseases